BPR5K230

BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC50 of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC50 of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1 6 in mouse models[1].

Product Specifications

CAS Number

[3029897-97-7]

UNSPSC

12352005

Target

TAM Receptor

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bpr5k230.html

Purity

99.82

Solubility

DMSO : 2 mg/mL (ultrasonic; warming; adjust pH to 3.8 with 1 M HCL; heat to 60°C)

Smiles

O=C(C1=CC=CN(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=C5C(OC(C6=CN(C)N=C6)=C5C7=CC=CC(CN(C)C)=C7)=NC=N4)C=C3

Molecular Formula

C37H30FN7O4

Molecular Weight

655.68

References & Citations

[1]Li MC, et al., Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment. J Med Chem. 2024 Jun 24.